What does Medtronic make?

Medtronic has 1 robot model on the DEPLOY registry: Hugo RAS (Medtronic builds both physical robots and the AI that runs them).

Is Medtronic publicly traded?

Yes. Medtronic is publicly traded on public markets, per the DEPLOY registry.

Who competes with Medtronic?

On the DEPLOY registry, peer companies to Medtronic building in the same form factors include Johnson & Johnson, Intuitive Surgical, LEM Surgical, MicroPort MedBot.

Who is the CEO of Medtronic?

Geoff Martha is the ceo of Medtronic, per the DEPLOY registry.

How can I invest in Medtronic?

Medtronic is publicly traded (public markets), so its shares can be bought through any broker.

Where is Medtronic headquartered?

Medtronic is headquartered in Dublin, Ireland.

Medtronic is publicly held by its shareholders.

Where does Medtronic operate robots?

Medtronic is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.

Is Medtronic a top robotics company?

On DEPLOY's intelligence score, which blends verified deployments, funding, hiring, media, safety, and IP signals, Medtronic ranks in roughly the top 64% of companies tracked by the registry.

Are there any incidents involving Medtronic?

6 active incidents involving Medtronic are on the DEPLOY registry. Each is a sourced, append-only record; retracted incidents are suppressed from this view.

Company

Medtronic

Global medical-device company (NYSE: MDT; founded 1949) whose Hugo RAS is the late-market robotic-assisted-surgery challenger to da Vinci; CE-marked 2021, US…

Track Medtronic

Founded: 1949
HQ: Dublin, Ireland
Status: public (NYSE: MDT)

Models

Deploy Watch

Track Medtronic on Deploy.

We notify you when a verified state change lands on the record, not when the company issues a claim.

Track Medtronic

Key facts

Product

Hugo RAS modular multi-port teleoperated surgical robot.

Gating events

CE mark Oct 2021; US FDA urology clearance Dec 3 2025 (urology only).

Stock listing

NYSE: MDT

Company type

Global medical-device company

Market positioning

Hugo RAS is positioned as a late-market challenger to da Vinci in robotic-assisted surgery

Data & sources

Press releases

Web sources

3 sources backing this record.View all →

Models (1)

View all models →

Current platform

Hugo RAS

Medtronic (NYSE: MDT; founded 1949 in Minneapolis, with legal headquarters in Dublin) makes the Hugo robotic-assisted surgery system, the late-market big-medtech challenger to Intuitive's da Vinci. Hugo is a modular multi-port teleoperated platform that received its European CE mark for urologic and gynecologic procedures on October 11, 2021, and, in the key regulatory milestone, US FDA clearance on December 3, 2025 for urologic procedures only, including prostatectomy, nephrectomy, and cystectomy, backed by the Expand URO investigational-device-exemption trial of 137 patients that met its primary safety and efficacy endpoints and was presented at AUA 2025. General-surgery and gynecologic US indications are planned submissions but are not yet cleared. The registry records Hugo at commercial maturity: it has been CE-marked and commercially used outside the US across more than 30 countries since 2021 and is now US-cleared for urology and entering US rollout. Medtronic discloses no specific system installed-base count, citing only tens of thousands of procedures across 30-plus countries, so the unit count is left as an honest absence rather than invented. On AI substance, Hugo is a master-slave teleoperated system whose Touch Surgery digital and video ecosystem is analytics and recording rather than autonomy, with no verified shipped intraoperative AI guidance.

surgicalView model →

Medtronic on the deployment map

Where Medtronic's robots are verified operating. Explore the deployment map by place and type.

Explainers

Plain-language answers to the questions people ask about Medtronic, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.
What is Medtronic Hugo?
Medtronic Hugo is the Hugo RAS (Robotic-Assisted Surgery) modular soft-tissue surgical system from Medtronic (NYSE: MDT). Per DEPLOY's surgical cluster framework: FDA IDE (Investigational Device Exemption) pivotal trial pathway US state (current submission posture operates at cap-flag pending primary-source verification); commercial in CE-Mark regions across EU + select international markets. Editorial throughline: large-prime IDE-pivotal pathway archetype within the surgical cluster's FDA-clearance-posture axis, contrasting Intuitive da Vinci market-leader cleared multi-procedure + J&J Ottava De Novo pre-market + CMR Versius international commercial soft-tissue. Hugo closes the Wave 1 surgical FDA-clearance triangle (Intuitive market-leader + Hugo IDE-pivotal + Ottava De Novo pre-market) that was the original framework's third leg missing from news anchors prior to this Wave 3 backfill.

Current leadership (6)

Geoff Martha Chairman & CEOIR-verified
Mike Marinaro EVP & President, Surgical OUIR-verified
Laura Mauri SVP, Chief Scientific/Medical/Regulatory OfficerIR-verified
Mike Marinaro presidentSEC-verified
Rajit Kamal executiveSEC-verified
Dr. James Porter cmoSEC-verified

Board (1)

Geoff Martha chair

Safety record

6 incidents on record (2 serious, 2 moderate, 2 minor). Most recent: Jul 2026.

serious: 2
moderate: 2
minor: 2

malfunction: 3
regulatory action: 2
injury: 1

Most recent: Jul 2026

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Medtronic (6)

Medtronic Hugo surgical robot earns FDA clearance for additional indication2026-07-01 · Regulatory action
Medtronic Hugo RAS: failure to calibrate with the application program freezing or failing to launch (FDA MAUDE)2026-05-21 · Malfunction
Medtronic Hugo RAS: unintended collision with the application program freezing or failing to launch (FDA MAUDE)2026-05-14 · Malfunction
Medtronic Hugo RAS: bipolar grasper broke and dropped a resin insulator fragment into a patient (FDA MAUDE)2026-05-11 · Injury
Medtronic Hugo robotic surgery system cleared by FDA for urologic procedures2026-02-15 · Regulatory action
Medtronic Hugo RAS: robotic arm froze during undocking, leading to bleeding and open conversion (FDA MAUDE)2026-01-16 · Malfunction

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.